Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
YH32364 is a new type of immunotherapy called a bispecific antibody that targets both Epidermal Growth Factor Receptor (EGFR) and 4-1BB. EGFR is a gene involved in cancer growth, and many cancer treatments aim to target it. 4-1BB, an immune-modulating protein, plays an important role in boosting T cell activity to combat cancer.
YH32364 is a treatment designed to activate 4-1BB specifically in tumors, aiming to avoid the liver-related side effects seen with previous 4-1BB treatments. It also helps block EGFR signals, assumed to make EGFR-targeted therapies more effective by overcoming resistance.
This study is consists of two parts. In Part 1, participants will be assigned sequentially to one of six dose levels, ranging from the lowest to the highest dose as determined by the sponsor, in order to identify an appropriate dosage.
In Part 2, participants will be randomly assigned to one of the two optimal dose levels identified in Part 1 to confirm the recommended dose.
The YH32364 will be administered via intravenous (IV) infusion once every two weeks. Participants will be required to visit the study site regularly for treatment and assessments. During all the visits, the doctors check participants' health and take note of any unwanted effects.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Operation Team 1
- Phone Number: +82-2-828-0150
- Email: clinicaltrials@yuhan.co.kr
Study Contact Backup
- Name: Chaebin Lee
- Phone Number: +82-2-828-0150
- Email: clinicaltrials@yuhan.co.kr
Study Locations
-
-
-
Seoul, South Korea, 03080
- Recruiting
- Seoul National University Hospital
-
Seoul, South Korea, 06351
- Recruiting
- Samsung Medical Center
-
Seoul, South Korea, 02841
- Recruiting
- Korea University Anam Hospital
-
Seoul, South Korea, 03722
- Recruiting
- Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must sign an informed consent form (ICF) prior to any study specific procedures
- ECOG performance status 0 or 1
- Estimated life expectancy of at least 3 months
- A woman must not be breastfeeding
- Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements.
[Dose Escalation Only] Locally advanced or metastatic EGFR overexpressing solid tumor* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy
* One of the following pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+) tumors.
- Head and neck squamous cell carcinoma (HNSCC)
- Non-small cell lung cancer (NSCLC): squamous cell carcinoma (SqCC)
- Esophageal squamous cell carcinoma (ESCC)
- Biliary tract cancer (BTC)
- Uterine cervical cancer
- Vulvar cancer
- Urothelial cancer
- Squamous cell carcinoma of other origin of tumor (e.g., skin squamous cell tumor)
[Dose Expansion Only] Cohort 1: Pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+), locally advanced or metastatic HNSCC other than nasopharyngeal carcinoma (NPC)* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy.
Exclusion Criteria:
- Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and/or carcinomatous meningitis
Have history of a second primary cancer with the exception of
- curatively treated non-melanomatous skin cancer
- curatively treated cervical or breast carcinoma in situ, or
- other malignancy with no known active disease present and no treatment administered during the last 2 years
- Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA)
- Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks
- Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis
- Have autoimmune disease that has required systemic treatment
- Infection with human immunodeficiency virus (HIV)
- Active chronic hepatitis B or chronic hepatitis C
[Prior/Concomitant Therapy]
- Have received systemic steroid therapy
- Previous treatment with a 4-1BB/CD137-modulating agent
- Have used a live vaccine within 4 weeks
- Have received treatment with immunotherapy, biological therapies, targeted small molecules, or hormonal therapies
- Have received radiation therapy
- Have received cytotoxic chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: YH32364
Dose Escalation Part: Dose Escalation part is designed to assess the safety and tolerability of YH32364 and to identify the Maximum Tolerated dose (MTD) and/or two dose levels for recommended dose (RD) selection. Dose Expansion Part: Dose Expansion part will consist of multiple cohorts by cancer types. Cohort 1 will be initiated to determine the RD after completion of Part 1. The RD will be determined among two dose levels investigated in Cohort 1 based on the totality of available data including PK, biomarkers, dose-response, safety, and efficacy. |
Dose Escalation Part: In this part, 6 dose levels are planned and approximately 30 patients will be enrolled. After each dose level, Safety Review Committee (SRC) will evaluate the available safety, tolerability, PK of YH32364 to decide the next dose. Dose Expansion Part: 50 participants with previously treated locally advanced or metastatic EGFR overexpressing HNSCC other than NPC will be randomized 1:1 ratio to each dose. (Cohort 1: Participants with locally advanced or metastatic EGFR overexpressing HNSCC other than NPC, whose disease progressed after or who are intolerable to all the available standard treatment) |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment-emergent adverse events (TEAEs) including dose limiting toxicities (DLTs)
Time Frame: Study Day 1 to Study Day 28 (during the DLTs evaluation period)
|
To assess the safety and tolerability of YH32364 in order to determine maximum tolerated dose (MTD) and select doses for dose optimization
|
Study Day 1 to Study Day 28 (during the DLTs evaluation period)
|
|
Objective Response Rate (ORR)
Time Frame: through dose expansion part completion, approximately 1.5 year
|
To assess the ORR of YH32364 at the recommended dose (RD) according to RECIST v1.1 by Investigator assessment
|
through dose expansion part completion, approximately 1.5 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the serum concentration-time curve from time 0 to the last quantifiable concentration (AUClast)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
AUC from time 0 to infinity (AUCinf)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Maximum observed serum concentration (Cmax)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Time to reach Cmax (Tmax)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Apparent terminal elimination half-life (t1/2)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Total clearance (CL)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Volume of distribution (Vd)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Volume of distribution at steady state (Vss)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
AUC during dosing interval at steady state (AUCtau)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Cmax at steady state (Cmax,ss)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Time to reach Cmax,ss (Tmax,ss)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Accumulation ratio (Rac)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Trough (predose) serum concentration on Cycle 4 (Ctrough)
Time Frame: through study completion, approximately 2.5 year
|
To characterize the pharmacokinetics (PK) of YH32364
|
through study completion, approximately 2.5 year
|
|
Presence and characterization of YH32364 ADA including neutralizing antibodies
Time Frame: through study completion, approximately 2.5 year
|
To explore the immunogenicity of YH32364
|
through study completion, approximately 2.5 year
|
|
Titer of YH32364 ADA
Time Frame: through study completion, approximately 2.5 year
|
To explore the immunogenicity of YH32364
|
through study completion, approximately 2.5 year
|
|
Objective Response Rate (ORR)
Time Frame: through dose escalation part completion, approximately 1 year
|
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
|
through dose escalation part completion, approximately 1 year
|
|
Duration of Response (DoR)
Time Frame: through study completion, approximately 2.5 year
|
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
|
through study completion, approximately 2.5 year
|
|
Disease Control Rate (DCR)
Time Frame: through study completion, approximately 2.5 year
|
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
|
through study completion, approximately 2.5 year
|
|
Depth of Response
Time Frame: through study completion, approximately 2.5 year
|
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
|
through study completion, approximately 2.5 year
|
|
Time to Response
Time Frame: through study completion, approximately 2.5 year
|
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
|
through study completion, approximately 2.5 year
|
|
Progression-free survival (PFS)
Time Frame: through study completion, approximately 2.5 year
|
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
|
through study completion, approximately 2.5 year
|
|
TEAEs
Time Frame: through dose expansion part completion, approximately 1.5 year
|
To assess the safety and tolerability of YH32364
|
through dose expansion part completion, approximately 1.5 year
|
|
Overall Survival (OS)
Time Frame: through dose expansion part completion, approximately 1.5 year
|
To assess the overall survival of YH32364 at the RD
|
through dose expansion part completion, approximately 1.5 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immune ORR (iORR)
Time Frame: through study completion, approximately 2.5 year
|
To assess the immune-related efficacy according to iRECIST by Investigator assessment
|
through study completion, approximately 2.5 year
|
|
Immune Duration of Response (iDOR)
Time Frame: through study completion, approximately 2.5 year
|
To assess the immune-related efficacy according to iRECIST by Investigator assessment
|
through study completion, approximately 2.5 year
|
|
Immune PFS (iPFS)
Time Frame: through study completion, approximately 2.5 year
|
To assess the immune-related efficacy according to iRECIST by Investigator assessment
|
through study completion, approximately 2.5 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yuhan Clinical Research Physician, Yuhan Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Uterine Diseases
- Genital Diseases, Female
- Lung Diseases
- Head and Neck Neoplasms
- Biliary Tract Diseases
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplastic Processes
- Esophageal Diseases
- Lung Neoplasms
- Genital Neoplasms, Female
- Carcinoma
- Neoplasms, Squamous Cell
- Uterine Cervical Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Uterine Neoplasms
- Carcinoma, Squamous Cell
- Vulvar Diseases
- Esophageal Neoplasms
- Pathological Conditions, Signs and Symptoms
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Biliary Tract Neoplasms
- Neoplasm Metastasis
- Carcinoma, Non-Small-Cell Lung
- Uterine Cervical Neoplasms
- Vulvar Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- YH32364-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to clinicaltrials@yuhan.co.kr
A summary of the study results will be posted in the publicly accessible database (i.e. clinicaltrials.gov) no later than 1 year after the study's primary completion date.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.